Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Theratechnologies Inc T.TH

Alternate Symbol(s):  THTX

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy. Its portfolio includes Phase I clinical trial of sudocetaxel zendusortide (TH1902), a novel peptide-drug conjugate (PDC), in patients with advanced ovarian cancer.


TSX:TH - Post by User

Bullboard Posts
Comment by ANALIAS00on Oct 12, 2018 10:00am
137 Views
Post# 28787568

RE:number of patients

RE:number of patients
I personnaly asked that question to Luc at the last Annual Shareholders meeting.  I asked him if he would find a way to provide us that info on a regular basis since that info is such useful for investors.
He says that he might provide it at the begging but would stop saying that sales would be the most important indicator and amount of patient would meen nothing after a while ...

I do not agree on that but that is what he gave me as an answer from what I remember.

I am 100% sure that prescriptions or amount of patients are clearly updated in RED or in GREEN on a Daily Dashboard at Theratechnologies so that info they have it.  Why not sharing ?  I have no idea.   I agree that sales is important at the end but it would be very useful to know how many patient are on the drug. 

Even as a potential patient that info would be useful.   I would ask how many patient are using that drug to have an idea if the drug is popular or not.

Sometime we can read reports or statistics about number of patient on this or that drugs.  So that info must be available somewhere somehow. 

On the other subject, by reading recent comments on this board but most of all because of the low Shareprice these days, it is going to be a veeeeerrrrryyyyyy long 4 month until next result  :o(

:o)

Bullboard Posts